Carbonyl J Derivatives: A New Class of HIV-1 Integrase Inhibitors
作者:Karl Maurer、Ann H. Tang、George L. Kenyon、Andrew D. Leavitt
DOI:10.1006/bioo.2000.1166
日期:2000.6
to treat HIV-1 infection. As such, newclasses of integraseinhibitors are needed. We have combined molecular modeling and combinatorial chemistry to identify and develop a newclass of HIV-1integraseinhibitors, the CarbonylJ [N,N'-bis(2-(5-hydroxy-7-naphthalenesulfonic acid)urea] derivatives. This newclass includes a number of compounds with sub-micromolar IC(50) values for inhibiting purified
[EN] RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS INHIBITEURS DE RAF KINASES ET LEURS PROCÉDÉS D'UTILISATION
申请人:ARRAY BIOPHARMA INC
公开号:WO2011025951A1
公开(公告)日:2011-03-03
Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
[EN] PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS<br/>[FR] INHIBITEURS DE RAF DE PYRAZOLE[3,4-B]PYRIDINE
申请人:ARRAY BIOPHARMA INC
公开号:WO2009111279A1
公开(公告)日:2009-09-11
Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
[EN] N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE N-(6-AMINOPYRIDIN-3-YL)-3-(SULFONAMIDO) BENZAMIDE COMME INHIBITEURS DE B-RAF POUR LE TRAITEMENT DU CANCER
申请人:ARRAY BIOPHARMA INC
公开号:WO2009111280A1
公开(公告)日:2009-09-11
Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Macrolactams are made by feeding aromatic amino acids as replacement starter units to a mutant strain of the geldanamycin-producing microorganism
Streptomyces hygroscopicus
var.
geldanus
NRRL 3602, wherein the gene cluster encoding enzymes for the biosynthesis of the natural starter unit 3-amino-5-hydroxybenzoic acid has been deleted.